Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists
@article{Albanese2003DihydroergocriptineIP, title={Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists}, author={Alberto Albanese and Carlo Colosimo}, journal={Acta Neurologica Scandinavica}, year={2003}, volume={107} }
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9–C10 and the lack of bromine in C2. DHEC has a potent D2‐like receptor agonist and a partial D1‐like receptor agonist activity; because of this biochemical profile, it…
14 Citations
Dopamine Agonists in Parkinson Disease : Special Focus on Pramipexole
- Psychology, Medicine
- 2008
In addition to abating the core symptoms of PD and delaying the onset of motor complications, the dopamine agonist pramipexole has been shown to ameliorate tremor and depressive symptoms in clinical practice.
Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture
- BiologyJournal of Neural Transmission
- 2005
The novel finding that the combination of a dopamine (DA) agonist, α-dihydroergocryptine (DHEC), with L-dopa or DA exerts a synergistic stimulatory effect on dopaminergic neurons in primary culture, while each substance alone had no or less effect is described.
Dopamine receptor agonists in the therapy of Parkinson’s disease
- Medicine, BiologyJournal of Neural Transmission
- 2003
It is concluded that there is little unequivocal evidence to suggest that any of the major dopamine receptor agonists should be invariably preferred in the therapy of Parkinson’s disease; their application must be based on the needs and responses of individual patients.
Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
- Medicine, BiologyCNS drugs
- 2010
Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate or advanced Parkinson’s disease as well as for the reduction of levodopa-related motor complications and other issues, including the efficacy of dopamine agonists for the treatment of non-motor symptoms, remain under evaluation.
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
- Medicine, BiologyClinical pharmacokinetics
- 2006
In general, initial dopamine receptor agonist monotherapy is associated with poorer motor performance and lower incidence of motor complications compared with levodopa, and CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data.
Group III metabotropic glutamate receptors as potential targets in the treatment of Parkinson's disease
- Biology
- 2006
Intranigral injections of L-SOP, L-AP4, PHCCC and (S)-3,4-DCPG were shown to reverse reserpine-induced akinesia, suggesting activation of mGlu4 and mGiu8 may underlie this effect, and data support the antiparkinsonian potential of group III mGLU.
Parkinson Disease in Primary Practice : Keys to Diagnosis and Management
- Medicine, Psychology
- 2008
This article is designed to provide primary clinicians with clinical criteria to better distinguish PD from other conditions with parkinsonian features and to present an evidencebased review of PD treatment.
Review of the available evidence on Oral Dopamine Agonists For Parkinson ’ s Disease
- Medicine
- 2014
Recommendations on the use of DAs from international guidelines on PD and grading systems adopted in the included guidelines Update of the Cochrane systematic review of dopamine agonist therapy in early Parkinson's disease.
Pharmacotherapy and Treatment of Parkinson's Disease
- Psychology, Medicine
- 2007
This chapter reviews the current practice of treatment for Parkinson's disease, with special emphasis on the management of treatment complications and non-motor manifestations of the disease.
Current and future therapeutic approaches in progressive supranuclear palsy.
- BiologyHandbook of clinical neurology
- 2008
References
SHOWING 1-10 OF 55 REFERENCES
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
- Medicine, PsychologyClinical neuropharmacology
- 1991
The authors demonstrate the efficacy and the good tolerability of DEK as a new DA agonist drug that can be added to LD in the treatment of parkinsonian patients.
Clinical usefulness of apomorphine in movement disorders.
- Medicine, PsychologyClinical neuropharmacology
- 1994
The available data suggest apomorphine (in conjunction with domperidone) as a first-choice treatment for the neuroleptic malignant syndrome and the temporary replacement of levodopa (e.g., after gastrointestinal surgery).
BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASE
- Medicine, PsychologyThe Lancet
- 1979
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
- Medicine, PsychologyNeurology
- 1997
It is indicated that pramipexole is safe and effective in the treatment of early Parkinson's disease and significantly reduced the severity of PD symptoms and signs compared with placebo.
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
- Medicine, PsychologyNeurology
- 1997
It is concluded that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points and in regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups, there was a trend to significance in favor of pramipingxole.
Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
- Medicine, BiologyActa neurologica Scandinavica
- 1999
Alpha‐dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of l‐dopa therapy long term motor complications (UPDRS part IV) as well as in Terms of the incidence and severity of adverse events.
A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease
- Psychology, MedicineCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- 1992
In this way symptomatic control is not compromised on theoretical grounds, but the cumulative levodopa dose is minimized in an effort to reduce the likelihood of free radical formation with their potential adverse consequences on disease progression.
Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine
- Medicine, PsychologyMovement disorders : official journal of the Movement Disorder Society
- 2001
An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome, suggesting a role for DHEC in the treatment of RLS.
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
- Psychology, MedicineAnnals of neurology
- 1990
The results of the present study suggest that changes in central dopaminergic mechanisms contributing to motor complications in advanced Parkinson's disease can be modified by procedures that provide continuous dopamine replacement.
Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study
- MedicineActa neurologica Scandinavica
- 2000
The results indicate that α‐dihydroergocryptine is safe and effective in improving symptoms of de novo parkinsonian patients.